Wu-tou decoction (WTD) has been extensively used for the treatment of rheumatoid arthritis (RA). Due to lack of appropriate methods, pharmacological mechanisms of WTD acting on RA have not been fully elucidated. In this study, a list of putative targets for compositive compounds containing in WTD were predicted by drugCIPHER-CS. Then, the interaction network of the putative targets of WTD and known RA-related targets was constructed and hub nodes were identified. After constructing the interaction network of hubs, four topological features of each hub, including degree, node betweenness, closeness and k-coreness, were calculated and 79 major hubs were identified as candidate targets of WTD, which were implicated into the imbalance of the nervous, endocrine and immune (NEI) systems, leading to the main pathological changes during the RA progression. Further experimental validation also demonstrated the preventive effects of WTD on inflammation and joint destruction in collagen-induced arthritis (CIA) rats and its regulatory effects on candidate targets both in vitro and in vivo systems. In conclusion, we performed an integrative analysis to offer the convincing evidence that WTD may attenuate RA partially by restoring the balance of NEI system and subsequently reversing the pathological events during RA progression.
Wu-tou decoction (WTD), as a classic TCM formula, was originally recorded in ''Jin Kui Yao Lve'' written by Chinese medical sage Zhang Zhongjing. It is prepared from a basic formula of five Chinese herbs, including Radix Aconiti (Wu Tou), Herba Ephedrae (Ma Huang), Radix Astragali (Huang Qi), Raidix Paeoniae Alba (Bai Shao) and Radix Glycytthizae (Gan Cao), and widely produced in China in accordance with the China Pharmacopoeia standard of quality control. In clinical practice, WTD has been extensively used for the treatment of rheumatic arthritis, RA, constitutional hypotension and hemicrania 5 . According to the TCM theory, multiple agents contained in one formula must work synergistically. With regard to WTD, Radix Aconiti is the primary component and is believed to be effective in treating rheumatic arthritis and RA; Herba Ephedrae serves as the ministerial component to intensify the analgesic function of Radix Aconiti; Radix Astragali acts as the adjunctive component to invigorate qi (vital energy), strengthen the body and reinforce the effect of Radix Aconiti and Herba Ephedrae; Raidix Paeoniae Alba and Radix Glycytthizae are both messenger drugs which can either focus the actions of the formula on a certain area of the body or harmonize and integrate the actions of the other herbs of the formula 6, 7 . Accumulating evidence has demonstrated that several compositive compounds of herbs in WTD, such as total alkaloids of Radix Aconiti, total glycosides and polysaccharides of Raidix Paeoniae Alba, and polysaccharides of Radix Astragali, may have excellent anti-inflammatory and anti-oxidant activities 8, 9 . However, monomer pharmacological effects can not present overall efficacy of the whole formula. Although our previous study of network analysis showed that the predicted effectors of WTD might be involved in neuroactive ligand-receptor interaction and calcium signaling pathway 10 , the pharmacological mechanisms of WTD acting on RA have not been fully elucidated.
Because a herbal formula with numerous compositive compounds is too complex to be detected solely by conventional experimental methods, there is an urgent need to develop new and appropriate approaches to address this problem. Network pharmacology, combined with pharmacology and pharmacodynamics, is a novel research field which is implicated in the application of omics and systems biology-based technologies 11 . It clarifies the synergistic effects and the underlying mechanisms of multi-component and multi-target agents by analyzing various networks of the complex and multi-levels interactions 12, 13 . There are two kinds of approaches in network pharmacology: 1) Bottom-up: Addition of well-known molecular drugs and observation of synergistic effects; 2) Top-down: Reduction of more general formula to its minimal elements that keep its beneficial properties 14, 15 . As a major tool in network pharmacology, the network analysis based on widely existing databases allows us to form an initial understanding of the action mechanisms within the context of systems-level interactions. Since TCM herbal formula has been considered as a multi-component and multi-target therapeutics which potentially meets the demands of treating a number of complex diseases in an integrated manner, the methodologies of network pharmacology are suitable for pursuing a priori knowledge about the combination rules embedded in formula 16 . Thus, the aim of the current study was to investigate the pharmacological mechanisms of WTD acting on RA through systems approaches integrating drug target prediction, network analysis and experimental validation as shown in Figure 1 .
Results and Discussion
Putative targets prediction for WTD. Following the drug target prediction by drugCIPHER-CS 14 , we assembled and ranked the 1746 druggable proteins which are often known targets in the DrugBank as putative targets for 451 compositive compounds containing in WTD after deleting redundancy. Of note, there were 101 (5.78%) putative targets identified as known RA-related targets.
The detailed information on the predicted drug targets for WTD is described in Supplementary Table S1 .
In addition, the top 100 targets were selected as target profiles for each herb since the top 100 targets reach the high prediction accuracy (77.3%) in general 14 . Twenty-three putative targets were common for all five herbs of WTD. More interestingly, Raidix Paeoniae Alba and Radix Glycytthizae shared more common putative targets with Radix Aconiti (both 36/100, 36.00%, Table 2 , five herbs of WTD shared 22 putative targets with known anti-RA drugs, suggesting the possible role of this formula in the treatment of RA. As an autoimmune disease, RA is caused by chronic imbalances between the nervous, endocrine and immune (NEI) systems which constitute systemic properties of an organism 18 . Vagus nerve activity is significantly suppressed in RA patients 19 . Acetylcholine, as the principal vagus neurotransmitter, inhibits inflammation by suppressing the production of pro-inflammatory cytokines that explains why acetylcholine is anti-inflammatory in nature 20 . Growing evidence has demonstrated that aconitine which is the main compositive compounds of Radix Aconiti has acetylcholine activity 21 . Consistently, CHRM1, CHRM3 and CHRNA2, which were all putative targets of Radix Aconiti shown in Table 2 , represent muscarinic acetylcholine receptors and neuronal acetylcholine receptor, and also successful therapeutic targets for RA treatment. In addition, glucocorticoids, an end product of the hypothalamic-pituitaryadrenal axis, are a mainstay treatment for many autoimmune diseases, including RA, because of their potent anti-inflammatory action 22 . Among putative targets of WTD shown in Table 2 , NR3C1, the common putative targets for three herbs Radix Astragali, Herba Ephedrae and Radix Aconiti, is a glucocorticoid receptor, indicating the glucocorticoid activity of WTD, which was in line with the findings of previous studies 23 . Moreover, pain management is an important component of RA patient care, and opioid analgesics have been extensively used for severe arthritis pain 24 . Accumulating studies have reported the analgesic effects of Radix Aconiti
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, in line with which, we identified three opioid receptors OPRM1, OPRK1 and OPRD1 as putative targets of this herb. From the point of view of immunopathology, RA represents a model for systemic T-cell mediated systemic autoimmunity leading to local cellular and autoantibody mediated chronic inflammation 26 . Thus, targeting of these elements with specific antagonists may interfere with the disease process, reestablishing tolerance and preventing further synovial inflammation. Among the putative targets of WTD shown in Table 2 , CD4, IL1B, TNF, NFKB2 and JUN are all involved in immunopathological changes during RA progression. Especially, recent studies have reported that WTD could attenuate the severity of RA or adjuvant arthritis rats by regulating CD4/CD8 ratio and expression levels of several cytokines such as IL1B and TNF 27, 28 . Taken together, WTD might exert the therapeutic efficacy in the treatment of RA through regulating the expression or activities of its putative targets which are implicated in restoring the balance of NEI system. Network analysis. In order to comprehensively understand the pharmacological mechanisms of WTD, we constructed the interaction network of putative targets and known RA-related targets. According to the previous study of Li et al. 29 , we identified a node as a hub if its degree is more than 2 fold of the median degree of all nodes in a network. Then, we constructed the network of direct interactions among these hub nodes (Please see the interaction network data in Supplementary Table S2 ). According to their associated biological processes or pathways, these hub nodes were implicated into the imbalance of NEI system, leading to the main pathological changes during the RA progression ( Figure 2 ). To screen the major hubs, 4 topological features, 'Degree,' 'Node betweenness', 'Closeness' and 'K value' (defined in 'Materials and methods' section), were calculated for each hub in the network. The median values of 'Degree', ' Node betweenness ', 'Closeness' and 'K value' were 21.00, 0.13, 39.34 and 14.00, respectively. Therefore, we determined that hubs with 'Degree'.21.00, ' Node betweenness'.0.13, 'Closeness'.39.34, and 'K value'.14.00 were major hubs. As a result, 121 major hubs were identified (Please see detail information on topological features of 121 major hubs in Supplementary Table S3 ). After selecting the intersection with putative targets of WTD (Supplementary Table S1 ), 79 major hubs were identified as candidate targets for this formula.
Pathway enrichment analysis. In the previous section, we found that the putative targets of WTD might play crucial roles in maintaining the balance of NEI system. Here, according to the pathway enrichment analysis (Supplementary Table S4 ), 79 candidate WTD targets with topological importance in drug-target network were significantly associated with NEI system including Neuroactive ligand-receptor interaction pathway, Progesterone-mediated oocyte maturation pathway, and immune-related pathways (Table 3) . Interestingly, targets of WTD were also enriched in the pathway of ''Rheumatoid arthritis'' ( Figure 3A , KEGG ID: hsa05323, http://www.genome.jp/ dbget-bin/www_bget?pathway1hsa05323), in which joint damage/ bone destruction, inflammation/synovial pannus formation and angiogenesis are three main pathological phenotypes of RA patients. Thus, we speculated that the anti-RA effects of WTD might be associated with the roles of its targets in reversing the imbalance of NEI system and subsequently in the regulation of downstream RArelated pathways, including osteoclast differentiation, T cell receptor signaling pathway, toll-like receptor signaling pathway and VEGF signaling pathway ( Figure 3B ), which are all associated with patients' phenotypes.
Among candidate WTD targets enriched in the ''Rheumatoid arthritis'' pathway, three acetylcholine receptors CHRM1, CHRM3 and CHRNA2, glucocorticoid receptor NR3C1, matrix metalloproteinase-(MMP)-1/MMP-13, IL-1b/TNF-a and hypoxia-inducible factor (HIF)-1a/VEGF axes have been indicated as key players of NEI system, osteoclast differentiation, inflammation and VEGF signaling pathway involved during RA progression, respectively. Since the regulatory effects of WTD on these candidate targets have not been fully elucidated, we further performed experimental validation to address this problem based on in vitro and in vivo systems.
Experimental validation. WTD decreases severity of arthritis in CIA rats. To investigate the effect of WTD on arthritis, the CIA model in SD rats was used. Although the disease manifested itself on different days after immunization, we did not observe a relation between clinical response and time of onset of disease. Oral administration of WTD, once a day started when the first clinical signs of disease were beginning, and continued for 21 days. As shown in Figure 4A , macroscopic evidence of arthritis such as erythema or swelling was markedly observed in vehicle-treated CIA rats, while doses of 1.9 g/ (kg?day) and 3.8 g/(kg?day) WTD significantly attenuated arthritis severity in CIA rats. Additionally, the mean arthritis score (all P ,0.05, Figure 4B ), the arthritis incidence (all P ,0.05, Figure 4C ), the percentage of arthritic limbs (all P ,0.05, Figure 4D ) and the time of arthritis first appeared (all P ,0.05, Figure 4E ) in WTD-treated rats were significantly lower than those in vehicle-treated CIA rats with a dose-dependent manner. Radiological and histopathological evaluation. Radiological and histopathological evaluation of knee joint sections of vehicle-treated CIA rats revealed inflammatory cell infiltration, synovial hyperplasia and partial bone destruction. In contrast, oral administration of WTD could distinctly reduce the extent of inflammatory cell infiltration, panus formation and bone destruction ( Figure 5A and 5B). To elucidate the effects of WTD treatment on inflammation and bone destruction at the radiological and histologic level, inflamed joints were scored with semiquantitative grading scales. As shown in Figure 5D and 5E, the inflammation scores and bone destruction scores in WTD-treated CIA rats were significantly decreased with a dose-dependent tendency in comparison with vehicle-treated CIA rats (all P ,0.05). MTX also reduced significantly the inflammation score and bone destruction score of inflamed joints compared with vehicle-treated CIA rats (P ,0.05, Figure 5D and 5E), although this value remained higher than those for WTD-treated groups. Moreover, the content of proteoglycan stained by safranin-O in inflamed joints were increased by WTD dose-dependently (all P ,0.05, Figure 5C and 5F).
WTD reverses the imbalance of NEI systems during RA progression partially by targeting three acetylcholine receptors CHRM1, CHRM3 and CHRNA2, and glucocorticoid receptor NR3C1. The imbalances of NEI systems have been regarded as one of the main causes of occurrence and progression of RA. In the current study, Western blot analysis was performed and the results in Figure 6 showed that the protein expression levels of three acetylcholine receptors CHRM1, CHRM3 and CHRNA2, and glucocorticoid receptor NR3C1 in inflamed joints of CIA rats were distinctly decreased compared with normal controls (all P ,0.01, Figure 6 ), which were all reversed by the treatment of WTD with a dose-depend manner (all P ,0.05, Figure 6 ). In addition, we found that Methotrexate, which is considered as the 'anchor drug' in RA treatment, could not change the expression levels of three acetylcholine receptors, implying there might be no drug-target interactions between Methotrexate and acetylcholine receptors. Moreover, Methotrexate significantly increased the expression of NR3C1 protein in the inflamed joints of CIA rats compared with vehicle controls (all P ,0.01, Figure 6E ), but had no differences with statistical significance when compared with WTDtreated groups. These findings suggest that WTD may reverse the imbalance of NEI systems during RA progression partially by regulating its candidate targets including CHRM1, CHRM3, CHRNA2 and NR3C1.
WTD reverses the main pathological events of RA by targeting MMP-1/MMP-13, IL-1b/TNF-a and HIF-1a/VEGF signal axes in vitro and in vivo systems. To obtain insights into the mechanisms of the inhibitory effects of WTD on cartilage-destruction in inflamed joints of CIA rats, the expression levels of MMP-1 and MMP-13 proteins in inflamed joints in different groups were detected by immunohistochemistry ( Figure 7) . Compared with vehicle-treated CIA rats, doses of 0.95 , 3.8 g/(kg?day) WTD significantly reduced the expression of MMP-1 (all P ,0.05, Figure 7A and C) and MMP-13 (all P ,0.05, Figure 7B and D). Methotrexate also significantly reduced the expression of MMP-1 and MMP-13 proteins in the inflamed joints of CIA rats compared with vehicle controls (all P ,0.01, Figure 7A ,D), although this value remained higher than those for WTD-treated groups (P ,0.05, Figure 7A,D) . These findings were all consistent with the data based on in vitro cultured human fibroblast-likesynoviocytes of RA (HFLS-RA) detected by western blot analysis as shown in Figure 7E ,G. Under the pathological conditions, especially in the progression of RA, the destruction of extracellular matrix (ECM) components may cause the impairment of joint functions 30 . Among ECM components, MMPs have been demonstrated to play a central role in this process. MMP-1 and MMP-13 expression levels have been found to be increased in syn- According to their associated biological processes or pathways, these hub nodes were implicated into the imbalance of nervous, endocrine and immune (NEI) system, leading to the main pathological changes during the RA progression. 31, 32 . In the present study, our data showed that the treatment of WTD significantly interfered with the RA-augmented expression of MMP-1 and MMP-13 proteins in vivo and in vitro systems, suggesting that WTD may prevent cartilage-destruction during the progression of RA by targeting MMP-1/MMP-13 axis.
In addition, we also detected the expression levels of IL-1b, TNFa, HIF-a and VEGF proteins in the sera of CIA rats and in HFLS-RA of different treatment groups by ELISA assay and western blot analysis, respectively, in order to investigate the possible mechanisms of WTD treatment on attenuating synovitis and angiogenesis in joints during RA progression. As a result, WTD treatments also markedly reduced the expression levels of IL-1b, TNF-a, HIF-a and VEGF proteins both in the sera of CIA rats and in HFLS-RA with a dosedependent tendency (all P ,0.05, Figure 8 ). Various inflammatory cytokines such as IL-1b, IL-6, and TNF-a have been found to be upregulated in synovial fluid from RA patients 33 . Among them, IL1b and TNF-a are known to be pivotal factors, since they strictly enhance the production of pro-MMPs and an inflammatory mediator, prostaglandin E2 (PGE2), in synoviocytes and chondrocytes 34 . Here, our data shown that the treatment of WTD could effectively reduce the expression of IL-1b and TNF-a at protein level both in the sera of CIA rats and in HFLS-RA, implying that WTD may suppress the synovitis in RA by targeting IL-1b/TNF-a axis. More interestingly, angiogenesis appears to play an important role in the pathogenesis of RA 35 . Recent studies have confirmed the overexpression of VEGF in sera and synovial fluid from RA patients. HIF-1a, as an essential regulatory factor of the transcription of the VEGF gene, has been demonstrated to be involved in the angiogenesis of RA 36 . In the current study, we found that the upregulation of both HIF-1a and VEGF proteins in sera from CIA rats and in HFLS-RA could be significantly suppressed by the treatment of WTD, indicating that this formula may have an anti-angiogenesis effect for RA by targeting HIF-1a/VEGF.
In conclusion, the current study provided an integrative analysis by combining drug target prediction and network analysis to understand the pharmacological mechanisms of WTD acting on RA. Further experimental validation also offered the convincing evidence that WTD may attenuate RA partially by restoring the balance of NEI system and subsequently reversing the pathological events during RA progression by regulating MMP-1/MMP-13, IL-1b/TNF-a and HIF-1a/VEGF signal axes.
Methods

Data preparation. Compositive compounds of each herb in WTD.
Compositive compounds of each herb in WTD were obtained from TCM Database@Taiwan 37 (http://tcm.cmu.edu.tw/, Updated in 2012-06-28), which is currently the largest noncommercial TCM database worldwide. TCM Database@Taiwan is based on information collected from Chinese medical texts and scientific publications, and contains more than 20,000 pure compounds isolated from 453 TCM herbs. In total, we collected the structural information of 22 compounds for Radix Aconiti, 122 compounds for Herba Ephedrae, 39 compounds for Radix Astragali, 65 compounds for Raidix Paeoniae Alba and 203 compounds for Radix Glycytthizae. The detailed information on these compositive compounds of each herb in WTD is described in Supplementary Table S5 .
Known RA-related targets. Known RA-related targets were obtained from four existing resources: (1) DrugBank database 38 (http://www.drugbank.ca/, version: 3.0). We only used those drug-target interactions whose drugs are FDA approved for the treatment of RA and whose targets are human genes/proteins. In total, we obtained 58 known RA-related targets. (2) The Online Mendelian Inheritance in Man (OMIM) database 39 (http://www.omim.org/, Last updated: October 31, 2013). We searched the OMIM database with a keyword ''rheumatoid arthritis'' and found 7 known RA-related targets: CD244, HLA-DR1B, MHC2TA, NFKBIL1, PAD, SLC22A4, and PTPN8. (3) Genetic Association Database (GAD) 40 (http:// geneticassociationdb.nih.gov/, Last updated: August 18, 2013). We used a keyword ''rheumatoid arthritis'' to search the GAD database. In total, we obtained 82 known RA-related targets whose association with RA was shown ''Y''. (4) Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database 41 (http://www. 47 , Database of Interacting Proteins (DIP) 48 , and PDZBase 49 . The detailed information on these PPI databases is described in Supplementary Table S7 .
Drug target prediction for WTD. The putative targets of WTD's compositive compounds were predicted by drug-CIPHER-CS presented by Zhao and Li 14 . Based on two hypotheses: (i) drugs with similar chemical structure usually bind functionally related proteins and (ii) functional relationship between the proteins can be measured by their distance in the protein interaction network, drugCIPHER-CS achieves good prediction performance and can infer drug targets in the genome-wide scale. This method calculates the likelihood of the interactions of drug-target based on the correlation between the query drug's structure similarity vector with the drug space and the candidate gene's functional similarity vector with the target space. For a query compound, drug-CIPHER-CS prioritizes the proteins in the PPI network according to the order of the decreasing drug target interaction likelihood, and the candidate proteins with high likelihood will be hypothesized as the putative targets.
Network construction. We first constructed a interaction network for known RArelated targets and putative drug targets of WTD based on their interaction data obtained from eight existing PPI databases as mentioned above. Then, we applied Navigator software (Version 2.2.1) to visualize the interaction network.
Defining network topological feature set. For each node i in interaction network, we defined four measures for assessing its topological property: (1) 'Degree' is defined as the number of links to node i; (2) 'Node betweenness' is defined as the number of shortest paths between pairs of nodes that run through node i. (3) 'Closeness' is defined as the inverse of the farness which is the sum of node i distances to all other nodes. The Closeness centrality can be regarded as a measure of how long it will take to spread information from node i to all other nodes sequentially. Degree, node betweenness and closeness centralities can measure a node's topological importance in the network. The larger a node's degree/node betweenness/closeness centrality is, the more important the node is in the interaction network 50 . (4) K-core analysis is an iterative process in which the nodes are removed from the networks in order of leastconnected 51 . The core of maximum order is defined as the main core or the highest kcore of the network. A k-core sub-network of the original network can be generated by recursively deleting vertices from the network whose degree is less than k. This results in a series of sub-networks that gradually reveal the globally central region of the original network. On this basis, 'K value' is used to measure the centrality of node i.
Pathway enrichment analysis for candidate WTD targets. We used Database for Annotation, Visualization and Integrated Discovery 52 (DAVID, http://david.abcc. ncifcrf.gov/home.jsp,version 6.7) for GO enrichment analysis. We also performed pathway enrichment analysis using pathway data obtained from the FTP service of KEGG 53 Animals. A total of 72 male SD rats (160 , 180 g) were purchased from Experimental Animal Center, Academy of Military Medical Sciences (production license No: SCXK 2002-001). All rats were maintained in a room equipped with an air-filtering system, and the cages and water were sterilized.
Cell culture. HFLS-RA (Cell Applications, USA) was used for the in vitro experimental validation in the current study. The cells were cultured in sterile synoviocyte growth medium (Cell Applications, USA) supplemented with 100 U/mL 1 penicillin, 80 U/mL 1 streptomycin, 2 mM Gln-glutamine, and were maintained at 37uC in a humidified 5% CO 2 incubator. HFLS-RA were used at passage numbers 4 to 8 in this study.
Induction of CIA. CIA was induced as our previously reported [54] [55] [56] . Briefly, bovine type II collagen (Chondrex, Redmond, WA, USA) was dissolved in 0.1 M acetic acid overnight at 4uC. This was emulsified in an equal volume of incomplete Freund's adjuvant (IFA, Chondrex, Redmond, WA, USA). The rats were immunized intradermally at the base of the tail with 100 ml of emulsion containing 100 mg of type II collagen. On day 7, rats were boosted intraperitoneally with 100 mg type II collagen in IFA.
Treatment and groups. According to the original composition of WTD recorded in Chinese Pharmacopoeia 2010 edition, WTD was prepared using the following procedure. The crude drugs of Radix Aconiti 6 g, Herba Ephedrae 9 g, Radix Astragali 9 g, Raidix Paeoniae Alba 9 g and Radix Glycytthizae 9 g were immersed in 2 litres of water for 2 h and then decocted to boil for 1 h. The decoction was filtered through four layers of gauze. Next, the drugs were boiled once again for 0.5 h with 2litres of water and the decoction was filtrated out with the above method. Finally, the extraction solution was made to a concentration of 1 g crude drug/mL. To clarify the chemical composition of WTD, UPLC-Q-TOF-MS analysis was conducted to identify its major compounds. The detailed strategy and results of the identification were provided in our previously published paper 57 . For in vivo experimental validation, the route of WTD delivery was oral administration. Treatment was given daily for a period of 21 days. The dosage selection for WTD [3.8 mg/(kg?day)] was nearly equivalent to RA patient dosage daily (42 g/ person/day). SD rats were divided into 6 groups with the equal number (n 5 12): normal control group (Normal), CIA model control group (Vehicle), CIA rats treated with 0.95 g/(kg?day) WTD (WTD-low), 1.9 g/(kg?day) WTD (WTD-middle), 3.8 g/(kg?day) WTD (WTD-high), and 0.2 mg/kg methotrexate (MTX).
For in vitro experimental validation, HFLS-RA were then incubated with different concentrations of WTD (0.05, 1.0 and 2.0 mg/mL) for 24 h.
Severity assessment of arthritis. Rats were observed once every day after primary immunization. Arthritis severity was evaluated by arthritis score, arthritis incidence, percentage of arthritic limbs and the time of arthritis first appeared which were performed by two independent, blinded observers. The arthritis score was the total of the scores for all 4 limbs (maximum possible arthritis score 80). Arthritis incidence values are the number positive/total number in group. In addition, the number of arthritic limbs of individual rats were counted and added to represent the number of arthritic limbs in a group. The percentage of arthritic limbs in a group was calculated as following formula: 
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Percentage of arthritic limbs~N umber of arthritic limbs in a group Number of all limbs in a group |100%
Moreover, the time of arthritis first appeared refered to the first day of the onset of the clinical symptoms of arthritis observed.
Histology and histologic scoring. Rats were sacrificed by cervical dislocation on day 21 after first immunication. Both hind limbs including the paws, ankles, and knees, were dissected, fixed immediately for 24 h in 4% paraformaldehyde, decalcified in 10% EDTA for up to 2 month at 4uC, and embedded in paraffin. Tissue sections (4 mm) were mounted on common slides for staining with hematoxylin and eosin (H&E) or safranin-O. All sections were randomized and evaluated by two trained observers who were blinded to the treatment groups and the arthritis severity of each rat. Minor differences between observers were resolved by mutual agreement. The data was expressed as mean inflammation score. All scores were based on a scale of 0-3, as previously described 58 .
Radiological observation. At the end of the experiment, rats were sacrificed and the left hind paws were radiographed with a digital mammography system (Planmed, Finland). Radiographs of ankle and tarsus joints of each rat were evaluated for bone destruction on a scale of 0 5 normal, 1 5 mild changes, 2 5 moderate changes, and 3 5 severe changes, respectively 59 . Two observers blind to treatment assignment and with significant experience in reading and rating radiographs for patients with RA evaluated the radiographs. A total radiological score was obtained by summing the scores awarded to the left hind paw by both observers, giving a maximum score of 6 per rat for each radiological parameter.
Immunohistochemical staining. Paraffin sections (5 mm) of tissue from the knee and ankle joints were mounted on poly-L-lysine-coated slides. Immunolocalizations of MMP-1 and MMP-13 in the joints were carried out with commercial Polink-2 plus Polymer HRP Detection System For Goat Primary Antibody kits (Golden Bridge International Inc., Mukilteo, WA, USA) according to the manufacturer's instructions. The paraffin sections were dewaxed by routine method and incubated for 10 min with 3% H 2 O 2 . Each section was incubated with normal goat serum for 20 min at room temperature, and then with primary antibodies against rat MMP-1 (Abcam, Cambridge, UK) and MMP-13 (Abcam, Cambridge, UK) respectively overnight at 4uC. After incubation with Polymer Helper for 20 min at 37uC, sections were reacted with poly-HRP anti-goat IgG for 20 min at 37uC. The sections were then stained with 3, 3-diaminobenzidine (Sigma, St. Louis, MO, USA) and counterstained with hematoxylin. For the control staining, PBS was used instead of the primary antibodies.
Specimens were examined using a Leica image analyzer and analyzed by computer image analysis (Leica Microsystem Wetzlar Gmbh., Wetzlar, Germany) in a blinded www.nature.com/scientificreports manner. To localize and identify areas with positively stained cells, ten digital images per specimen of synovium from a knee or ankle joint were recorded, and quantitative analysis was performed according to the color cell separation. The results are expressed as the mean region of interest, representing the percentage of area covered with positively stained cells per image at a magnification of 3400.
Enzyme-linked immunosorbant assay. Sera from the rats on day 22 of arthritis were obtained and stored at 280uC until use. The amounts of IL-1b, TNF-a, HIF-1a and VEGF in sera were detected by ELISA assay (R&D system, Minneapolis, MN, USA) according to the manufacturer's protocol and absorbance was measured at 450 nm. All experiments were done in triplicate.
Western blot analysis. The Western blot protocol and semiquantitative analysis were carried out following the protocol of our previous studies 54, 56 . The following antibodieswere used: IL-1b antibody (rabbit monoclonal antibody, dilution 1520000, Abcam.UK), TNF-a antibody (rabbit polyclonal antibody, dilution 15100, Abcam. UK), VEGF antibody (rabbit monoclonal antibody, dilution 151000, Abcam. UK), HIF-1a antibody (rabbit monoclonal antibody, dilution 151000, Abcam. UK), MMP-1 antibody (rabbit monoclonal antibody, dilution 151000, Abcam. UK), MMP-13 antibody (rabbit monoclonal antibody, dilution 15500, Abcam. UK), CHRM1 antibody (rabbit polyclonal antibody, dilution 15500, Abcam. UK), CHRM3 antibody (rabbit monoclonal antibody, dilution 151000, Abcam. UK), CHRNA2 antibody (rabbit monoclonal antibody, dilution 151000, Abcam. UK), NR3C1 antibody (rabbit monoclonal antibody, dilution 1550000, Abcam. UK). All experiments were done in triplicate. Mean normalized protein expression 6 SEM was calculated from independent experiments.
Statistical analysis. The software of SPSS version13.0 for Windows (SPSS Inc, Chicago, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was used for statistical analysis. Continuous variables were expressed as X+s. Arthritis incidence and percentage of arthritic limbs were analyzed by a chi-square test. Arthritis index and pathological score were analyzed with non-parametric statistics (Kruskal-Wallis test). Other data were analyzed by one-way ANOVA followed by LSD test. Differences were considered statistically significant when P was less than 0.05.
